OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
VANCOUVER, British Columbia, April 19, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization process, the Company’s request to voluntarily delist its common shares on the Toronto Stock Exchange ("TSX") at the close of markets on May 3, 2017 has been granted. The Company’s shares will continue to trade on the NASDAQ Global Select Market under the symbol “NVLN”.
The Company believes that the low trading volume of its shares on the TSX over a sustained period no longer justifies the financial and administrative costs associated with maintaining a dual listing. Canadian shareholders will be able to continue to trade the Company’s shares on the NASDAQ exchange through their brokers who have U.S. registered broker-dealer affiliates.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
